Who
Noah Goodman
Chief Business Officer
Company insider
Files Form 4 as: Chief Business Officer, Kymera Therapeutics.
In numbers
- Trades disclosed
- 36
- Buys
- 0
- Sells
- 6
- Bought
- $0
- Sold
- $4.4M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 8 Apr 2025
- Last trade
- 1 Jul 2026
- Last filed
- 2 Jul 2026
Companies traded
Activity over time
1 Apr – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Jul 2026filed 2 Jul 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $387K3,389 at $114.29 | filing |
| 1 Jul 2026filed 2 Jul 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $387K3,389 at $114.29 | filing |
| 25 Jun 2026filed 25 Jun 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Code M | $105K5,000 at $21.05 | filing |
| 25 Jun 2026filed 25 Jun 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $273K2,500 at $109.00 | filing |
| 25 Jun 2026filed 25 Jun 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $298K2,500 at $119.00 | filing |
| 25 Jun 2026filed 25 Jun 2026 | KYMR Kymera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,000 at $0.00 | filing |
| 25 Jun 2026filed 25 Jun 2026 | KYMR Kymera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,000 at $0.00 | filing |
| 25 Jun 2026filed 25 Jun 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Code M | $105K5,000 at $21.05 | filing |
| 25 Jun 2026filed 25 Jun 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $273K2,500 at $109.00 | filing |
| 25 Jun 2026filed 25 Jun 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $298K2,500 at $119.00 | filing |
| 22 Jun 2026filed 22 Jun 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Code M | $53K2,500 at $21.05 | filing |
| 22 Jun 2026filed 22 Jun 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $248K2,500 at $99.00 | filing |
| 22 Jun 2026filed 22 Jun 2026 | KYMR Kymera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,500 at $0.00 | filing |
| 22 Jun 2026filed 22 Jun 2026 | KYMR Kymera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,500 at $0.00 | filing |
| 22 Jun 2026filed 22 Jun 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Code M | $53K2,500 at $21.05 | filing |
| 22 Jun 2026filed 22 Jun 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $248K2,500 at $99.00 | filing |
| 14 Apr 2026filed 16 Apr 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $121K1,347 at $90.00 | filing |
| 14 Apr 2026filed 16 Apr 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $121K1,347 at $90.00 | filing |
| 10 Apr 2026filed 10 Apr 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $175K2,000 at $87.35 | filing |
| 10 Apr 2026filed 10 Apr 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $175K2,000 at $87.35 | filing |
News
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR)KYMR · prnewswire.com · 12 Oct 2026
0 headlines in the last 90 days name Noah Goodman; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.